Key facts
- This page summarizes Jason Matuszewski's Form 3 filing for BioStem Technologies, Inc. (BSEM).
- 0 reported transactions and 7 derivative rows are listed below.
- Accepted by SEC: 14 Aug 2026, 19:09.
Jason Matuszewski - 06 Aug 2026 Form 3 Insider Report for BioStem Technologies, Inc. (BSEM)
- Reporting relationship
- Chief Executive Officer, Director, 10%+ Owner
- Issuer ticker
- BSEM
- Reported as of
- 06 Aug 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Jason Matuszewski
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Jason Matuszewski filed Form 3 for BioStem Technologies, Inc. (BSEM) on 14 Aug 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001634730
Primary reporting owner
Matuszewski Jason
- Relationship
- Chief Executive Officer, Director, 10%+ Owner
- Address
- C/O BIOSTEM TECHNOLOGIES, INC., 2836 CENTER PORT CIRCLE, POMPANO BEACH
- Signature
- /s/ Jason Matuszewski
- Signature date
- 14 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BSEM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,278,433
- Date
- 06 Aug 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BSEM
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,250,000
- Exercise price
- $2.00
- Footnotes
- F1
BSEM
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 198,807
- Exercise price
- $10.05
- Footnotes
- F2
BSEM
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,427
- Exercise price
- $10.05
- Footnotes
- F3
BSEM
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 440,529
- Exercise price
- $5.50
- Footnotes
- F4
BSEM
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42,343
- Exercise price
- Footnotes
- F5, F6
BSEM
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 116,550
- Exercise price
- Footnotes
- F6, F7
BSEM
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 363,636
- Exercise price
- Footnotes
- F6, F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
These options are fully vested and exercisable.
Footnote F2
These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
Footnote F3
These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
Footnote F4
These options vest according to the following schedule: 33% will vest on February 11, 2027, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
Footnote F5
These restricted stock units vest in equal quarterly installments over 3 years from the grant date (September 15, 2024).
Footnote F6
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
Footnote F7
These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Footnote F8
These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.